"Oct. 23, 2012 -- Wider use of colonoscopy has led to a more dramatic decline in colorectal cancer rates, a new study suggests.
Colorectal cancer cases and deaths have been falling for decades, with the most recent decline likely due t"...
Vectibix Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Vectibix (panitumumab) Injection is a cancer medication used to treat metastatic colorectal cancer that has progressed after treatment with other chemotherapy. Common side effects include diarrhea, nausea, vomiting, tiredness, constipation, abdominal pain, or growth of eyelashes.
The recommended dose of Vectibix is 6 mg/kg, administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes. Vectibix may interact with other drugs. Tell your doctor all medications and supplements you use. Vectibix is not recommended for use during pregnancy. It may harm a fetus. Consult your doctor to discuss using at least 2 forms of birth control (e.g., condoms, birth control pills) while receiving this medication and for 6 months after the end of treatment. If you become pregnant or think you may be pregnant, tell your doctor. Based on information from related drugs, this medication may pass into breast milk. Breastfeeding is not recommended while using Vectibix and for 2 months after the end of treatment.
Our Vectibix (panitumumab) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Vectibix in Detail - Patient Information: Side Effects
Some people receiving a panitumumab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, itchy, short of breath, or if you have a fever or chills during the injection.
Some of the side effects of panitumumab may not appear when you first start using the medication. Severe skin or eye reactions may occur up to 2 weeks after the start of your treatment. These effects may not clear up for weeks or even months after you stop receiving panitumumab.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
- fever, sore throat, and headache with a severe blistering, peeling, and red skin rash;
- swelling of your hands or ankles;
- acne, dryness, peeling, cracking, bleeding, oozing, pus, or any other sign of skin infection;
- cough or wheezing, running out of breath easily;
- white patches or sores inside your mouth or on your lips;
- drowsiness, restless feeling, confusion, muscle stiffness, fast or uneven heart rate, chest pain;
- redness, swelling, or irritation of your eyes or eyelids; or
- swelling or infection around your fingernails or toenails.
Less serious side effects may include:
- nausea, vomiting, stomach pain;
- diarrhea or constipation; or
- tired feeling.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Vectibix (Panitumumab Injection for Intravenous Use) »
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Vectibix Overview - Patient Information: Side Effects
Diarrhea, nausea, vomiting, tiredness, constipation, abdominal pain, or growth of eyelashes may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor right away if you have any serious side effects, including: swelling ankles/feet, unusual weakness, irregular heartbeat, severe muscle spasms, mouth sores, eye redness/itching/irritation, watery eyes, menstrual changes.
Prolonged and/or severe diarrhea may lead to a loss of too much body water and minerals (dehydration). Tell your doctor right away if you develop any of the following: extreme thirst, decreased urination, dizziness, fainting.
Rarely, panitumumab has caused very serious lung disease. Tell your doctor immediately if you develop symptoms of lung disease, including: cough, shortness of breath.
A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Vectibix (Panitumumab Injection for Intravenous Use)»
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Vectibix FDA Prescribing Information: Side Effects
The following adverse reactions are discussed in greater detail in other sections of the label:
- Dermatologic and Soft Tissue Toxicity [see BOXED WARNING, DOSAGE AND ADMINISTRATION, and WARNINGS AND PRECAUTIONS]
- Increased Tumor Progression, Increased Mortality, or Lack of Benefit in KRAS-Mutant mCRC [see INDICATIONS AND USAGE and WARNINGS AND PRECAUTIONS]
- Electrolyte Depletion/Monitoring [see WARNINGS AND PRECAUTIONS]
- Infusion Reactions [see DOSAGE AND ADMINISTRATION, and WARNINGS AND PRECAUTIONS]
- Acute Renal Failure in Combination with Chemotherapy [see WARNINGS AND PRECAUTIONS]
- Pulmonary Fibrosis/Interstitial Lung Disease (ILD) [see WARNINGS AND PRECAUTIONS]
- Photosensitivity [see WARNINGS AND PRECAUTIONS]
- Ocular Toxicities [see WARNINGS AND PRECAUTIONS]
- Increased Mortality and Toxicity with Vectibix in combination with Bevacizumab and Chemotherapy [see WARNINGS AND PRECAUTIONS]
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical studies does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
Safety data are presented from two clinical trials in which patients received Vectibix: Study 1, an open-label, multinational, randomized, controlled, monotherapy clinical trial (N = 463) evaluating Vectibix with best supportive care (BSC) versus BSC alone in patients with EGFR-expressing mCRC and Study 3, a randomized, controlled trial (N = 1183) in patients with mCRC that evaluated Vectibix in combination with FOLFOX chemotherapy versus FOLFOX chemotherapy alone. Safety data for Study 3 are limited to 656 patients with wild-type KRAS mCRC.
In Study 1, the most common adverse reactions ( ≥ 20%) with Vectibix were skin rash with variable presentations, paronychia, fatigue, nausea, and diarrhea.
The most common ( > 5%) serious adverse reactions in the Vectibix arm were general physical health deterioration and intestinal obstruction. The most frequently reported adverse reactions for Vectibix leading to withdrawal were general physical health deterioration (n = 2) and intestinal obstruction (n = 2).
For Study 1, the data described in Table 1 and in other sections below, except where noted, reflect exposure to Vectibix administered to patients with mCRC as a single agent at the recommended dose and schedule (6 mg/kg every 2 weeks).
Table 1: Adverse Reactions ( ≥ 5% Difference)
Observed in Patients Treated with Vectibix Monotherapy and Best Supportive Care
Compared to Best Supportive Care Alone (Study 1)
|SYSTEM ORGAN CLASS Preferred Term||Study 1|
|Vectibix Plus Best Supportive Care
(N = 229)
|Best Supportive Care
(N = 234)
|Growth of eyelashes||13 (6)|
|Nausea||52 (23)||2 ( < 1)||37 (16)||1 ( < 1)|
|Diarrhea||49 (21)||4 (2)||26 (11)|
|Vomiting||43 (19)||6 (3)||28 (12)||2 ( < 1)|
|Stomatitis||15 (7)||2 ( < 1)|
|GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS|
|Fatigue||60 (26)||10 (4)||34 (15)||7 (3)|
|Mucosal inflammation||15 (7)||1 ( < 1)||2 ( < 1)|
|INFECTIONS AND INFESTATIONS|
|Paronychia||57 (25)||4 (2)|
|RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS|
|Dyspnea||41 (18)||12 (5)||30 (13)||8 (3)|
|Cough||34 (15)||1 ( < 1)||17 (7)|
|SKIN AND SUBCUTANEOUS TISSUE DISORDERS|
|Erythema||150 (66)||13 (6)||2 ( < 1)|
|Pruritus||132 (58)||6 (3)||4 (2)|
|Acneiform dermatitis||131 (57)||17 (7)||2 ( < 1)|
|Rash||51 (22)||3 (1)||2 ( < 1)|
|Skin fissures||45 (20)||3 (1)||1 ( < 1)|
|Exfoliative rash||41 (18)||4 (2)|
|Dry skin||23 (10)|
|Nail disorder||22 (10)|
|Skin exfoliation||21 (9)||2 ( < 1)|
|Skin ulcer||13 (6)||1 ( < 1)|
Adverse reactions in Study 1 that did not meet the threshold criteria for inclusion in Table 1 were conjunctivitis (4.8% vs < 1%), dry mouth (4.8% vs 0%), pyrexia (16.6% vs 13.2%), chills (3.1% vs < 1%), pustular rash (4.4% vs 0%), papular rash (1.7% vs 0%), dehydration (2.6% vs 1.7%), epistaxis (3.9% vs 0%), and pulmonary embolism (1.3% vs 0%).
In Study 1, dermatologic toxicities occurred in 90% of patients receiving Vectibix. Skin toxicity was severe (NCICTC grade 3 and higher) in 15% of patients. Ocular toxicities occurred in 16% of patients and included, but were not limited to, conjunctivitis (5%). One patient experienced an NCI-CTC grade 3 event of mucosal inflammation. The incidence of paronychia was 25% and was severe in 2% of patients [see WARNINGS AND PRECAUTIONS].
In Study 1 (N = 229), median time to the development of dermatologic, nail, or ocular toxicity was 12 days after the first dose of Vectibix; the median time to most severe skin/ocular toxicity was 15 days after the first dose of Vectibix; and the median time to resolution after the last dose of Vectibix was 98 days. Severe toxicity necessitated dose interruption in 11% of Vectibix-treated patients [see DOSAGE AND ADMINISTRATION].
Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, necrotizing fasciitis, and abscesses requiring incisions and drainage were reported.
Vectibix in Combination with FOLFOX Chemotherapy
The most commonly reported adverse reactions ( ≥ 20%) in patients with wild-type KRAS mCRC receiving Vectibix (6 mg/kg every 2 weeks) and FOLFOX therapy (N = 322) in Study 3 were diarrhea, stomatitis, mucosal inflammation, asthenia, paronychia, anorexia, hypomagnesemia, hypokalemia, rash, acneiform dermatitis, pruritus, and dry skin (Table 2). Serious adverse reactions ( ≥ 2% difference between treatment arms) in Vectibix-treated patients with wild-type KRAS mCRC were diarrhea and dehydration. The commonly reported adverse reactions ( ≥ 1%) leading to discontinuation in patients with wild-type KRAS mCRC receiving Vectibix were rash, paresthesia, fatigue, diarrhea, acneiform dermatitis, and hypersensitivity. One grade 5 adverse reaction, hypokalemia, occurred in a patient who received Vectibix.
Table 2: Adverse Reactions ( ≥ 5% Difference)
Observed in Patients with Wild-type (WT) KRAS Tumors Treated with Vectibix and
FOLFOX Chemotherapy Compared to FOLFOX Chemotherapy Alone (Study 3)
|SYSTEM ORGAN CLASS
|Vectibix Plus FOLFOX
(n = 322)
(n = 327)
|Conjunctivitis||58 (18)||5 (2)||10 (3)|
|Diarrhea||201 (62)||59 (18)||169 (52)||29 (9)|
|Stomatitis||87 (27)||15 (5)||42 (13)||1 ( < 1)|
|GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS|
|Mucosal inflammation||82 (25)||14 (4)||53(16)||1 ( < 1)|
|Asthenia||79 (25)||16 (5)||62 (19)||11 (3)|
|INFECTIONS AND INFESTATIONS|
|Paronychia||68 (21)||11 (3)|
|Weight decreased||58 (18)||3 ( < 1)||22 (7)|
|METABOLISM AND NUTRITION DISORDERS|
|Anorexia||116 (36)||14 (4)||85 (26)||6 (2)|
|Hypomagnesemia||96 (30)||21 (7)||26 (8)||1 ( < 1)|
|Hypokalemia||68 (21)||32 (10)||42 (13)||15 (5)|
|Dehydration||26 (8)||8 (2)||10 (3)||5 (2)|
|RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS|
|Epistaxis||46 (14)||30 (9)|
|SKIN AND SUBCUTANEOUS TISSUE DISORDERS|
|Rash||179 (56)||55 (17)||24 (7)||1 ( < 1)|
|Acneiform dermatitis||104 (32)||33 (10)|
|Pruritus||75 (23)||3 ( < 1)||14 (4)|
|Dry skin||68 (21)||5 (2)||13 (4)|
|Erythema||50 (16)||7 (2)||14 (4)|
|Skin fissures||50 (16)||1 ( < 1)||1 ( < 1)|
|Alopecia||47 (15)||30 (9)|
|Acne||44 (14)||10 (3)||1 ( < 1)|
|Nail disorder||32 (10)||4 (1)||4 (1)|
|Palmar-plantar erythrodysesthesia syndrome||30 (9)||4 (1)||9 (3)||2 ( < 1)|
Adverse reactions that did not meet the threshold criteria for inclusion in Table 2 were abdominal pain (28% vs 23%), localized infection (3.7% vs < 1%), cellulitis (2.5% vs 0%), hypocalcemia (5.6% vs 2.1%), and deep vein thrombosis (5.3% vs 3.1%).
Infusional toxicity manifesting as fever, chills, dyspnea, bronchospasm or hypotension was assessed within 24 hours of an infusion during the clinical study. Vital signs and temperature were measured within 30 minutes prior to initiation and upon completion of the Vectibix infusion. The use of premedication was not standardized in the clinical trials. Thus, the utility of premedication in preventing the first or subsequent episodes of infusional toxicity is unknown. Across clinical trials of Vectibix monotherapy, 3% (24/725) experienced infusion reactions of which < 1% (3/725) were severe (NCI-CTC grade 3-4). In one patient, Vectibix was permanently discontinued for a serious infusion reaction [see DOSAGE AND ADMINISTRATION].
As with all therapeutic proteins, there is potential for immunogenicity. The immunogenicity of Vectibix has been evaluated using two different screening immunoassays for the detection of binding anti-panitumumab antibodies: an acid dissociation bridging enzyme-linked immunosorbent assay (ELISA) detecting high-affinity antibodies and a Biacore® biosensor immunoassay detecting both high-and low-affinity antibodies. For patients whose sera tested positive in screening immunoassays, an in vitro biological assay was performed to detect neutralizing antibodies.
The incidence of binding anti-panitumumab antibodies (excluding preexisting and transient positive patients) was 0.4% (5/1123) as detected by the acid dissociation ELISA and 3.2% (36/1123) as detected by the Biacore® assay. The incidence of neutralizing anti-panitumumab antibodies (excluding preexisting and transient positive patients) was 0.8% (9/1123). There was no evidence of altered pharmacokinetic or safety profiles in patients who developed antibodies to Vectibix.
In combination with chemotherapy: The incidence of binding anti-panitumumab antibodies (excluding preexisting positive patients) was 0.9% (12/1297) as detected by the acid dissociation ELISA and 0.7% (9/1296) as detected by the Biacore® assay. The incidence of neutralizing anti-panitumumab antibodies (excluding preexisting positive patients) was 0.2% (2/1297). No evidence of an altered safety profile was found in patients who developed antibodies to Vectibix.
The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to panitumumab with the incidence of antibodies to other products may be misleading.
The following adverse reactions have been identified during post-approval use of Vectibix. Because these reactions are reported in a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
- Skin and subcutaneous tissue disorders: Skin necrosis, angioedema [see BOXED WARNING, DOSAGE AND ADMINISTRATION, and WARNINGS AND PRECAUTIONS]
- Immune system disorders: Infusion reaction [see DOSAGE AND ADMINISTRATION and WARNINGS AND PRECAUTIONS]
- Eye disorders: Keratitis/ulcerative keratitis [see WARNINGS AND PRECAUTIONS]
Read the entire FDA prescribing information for Vectibix (Panitumumab Injection for Intravenous Use) »
Additional Vectibix Information
Vectibix - User Reviews
Vectibix User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.